New trial shows oral semaglutide reduces cardiovascular events in diabetes patients

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention for their effectiveness against weight gain, high blood sugar, and even alcohol cravings.

Leave a Reply